Redox Biology:研究发现内源性胆固醇酯氧化产物影响胆固醇水平的新机制

2018-12-18 佚名 上海营养与健康研究院

近日,国际学术期刊Redox Biology 在线发表了中国科学院上海营养与健康研究院尹慧勇研究组的最新研究成果“Endogenous cholesterol ester hydroperoxides modulate cholesterol levels and inhibit cholesterol uptake in hepatocytes and macrophages”。该研究利用靶向脂

近日,国际学术期刊Redox Biology 在线发表了中国科学院上海营养与健康研究院尹慧勇研究组的最新研究成果“Endogenous cholesterol ester hydroperoxides modulate cholesterol levels and inhibit cholesterol uptake in hepatocytes and macrophages”。该研究利用靶向脂质组学的方法系统分析了不同阶段血管病人血浆中来源于胆固醇酯的多种氧化产物,发现不同类型的血管疾病中,氧化胆固醇酯(Oxidized cholesterol ester, oxCEs)的水平显着不同,并且在心梗病人中明显升高。然后利用化学合成的方法得到一种主要的过氧化产物(cholesteryl-13(cis,trans)-hydroperoxy-octadecadienoate, ch-13(c,t)-HpODE),并进一步在体内体外探究该氧化产物对胆固醇水平的影响,同时初步揭示了胆固醇酯过氧化物影响胆固醇水平的新机制。

心血管疾病是目前发病率和死亡率最高的疾病之一,胆固醇代谢紊乱是造成心血管疾病的重要原因之一。既往研究表明氧化低密度脂蛋白(Oxidized Low Density Lipoprotein, oxLDL)在动脉粥样硬化中具有重要的作用,然而关于其内在成分——氧化胆固醇酯却少有研究。近年来,有研究表明在动脉粥样硬化斑块中oxCEs的存在,但是由于oxCEs的种类及结构复杂性,无论是对于其临床样本的分析检测还是生物学活性的研究都极具挑战。

该研究利用靶标脂质组学技术分析正常对照组(Healthycontrols,Con)、冠心病组(Coronary heart disease, CHD)、心脑血管合并组(CHD+Cerebrovascular disease, CHD+CBD)及心梗组(Myocardial infraction, MI)的血浆样本。结果表明,疾病不同阶段具有明显不同的氧化胆固醇酯水平,并且在MI组明显上升。随后化学合成并纯化了一种主要的内源性oxCE,用于研究该类内源性代谢物对胆固醇代谢的作用。体内实验结果表明,ch-13(c,t)-HpODE可以减少肝脏和腹腔巨噬细胞的胆固醇含量,并增加血浆胆固醇的水平。通过体外实验发现,ch-13(c,t)-HpODE可以通过激活LXRα-IDOL-LDLR通路,抑制巨噬细胞的胆固醇摄入;同时,ch-13(c,t)-HpODE所引起的肝细胞胆固醇摄入的减少同样依赖于LDLR和LXRα。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1753451, encodeId=ba441e5345143, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Apr 22 03:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767580, encodeId=05c01e67580ff, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Feb 24 20:48:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918432, encodeId=9b7519184322e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 11 11:48:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682032, encodeId=979e16820328a, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Sun Sep 01 19:48:00 CST 2019, time=2019-09-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1753451, encodeId=ba441e5345143, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Apr 22 03:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767580, encodeId=05c01e67580ff, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Feb 24 20:48:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918432, encodeId=9b7519184322e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 11 11:48:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682032, encodeId=979e16820328a, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Sun Sep 01 19:48:00 CST 2019, time=2019-09-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1753451, encodeId=ba441e5345143, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Apr 22 03:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767580, encodeId=05c01e67580ff, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Feb 24 20:48:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918432, encodeId=9b7519184322e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 11 11:48:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682032, encodeId=979e16820328a, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Sun Sep 01 19:48:00 CST 2019, time=2019-09-01, status=1, ipAttribution=)]
    2019-08-11 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1753451, encodeId=ba441e5345143, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Apr 22 03:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767580, encodeId=05c01e67580ff, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Feb 24 20:48:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918432, encodeId=9b7519184322e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 11 11:48:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682032, encodeId=979e16820328a, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Sun Sep 01 19:48:00 CST 2019, time=2019-09-01, status=1, ipAttribution=)]

相关资讯

美国新版胆固醇指南十大要点:极高危患者LDL-C不能达到<1.8 mmol/L时,应依次使用依折麦布和PCSK9抑制剂

在美国心脏协会(AHA)2018年学术年会上,新版胆固醇指南公布。新版指南进一步支持胆固醇“低一点,好一点”的理论。

美国新指南建议:这类人要从2岁开始查胆固醇

美国心脏病协会近日发布新版血液胆固醇管理指南,指出高胆固醇水平增加心脏病发作或中风等风险,各个年龄段的人都应关注胆固醇水平,高危人群应从幼儿时期就做相关检查,以减少心血管疾病患病风险。新指南建议医生详细评估人们的心血管疾病风险,并帮助制订个性化预防计划。

2018AHA/ACC胆固醇临床实践指南更新:新指南,新在哪?

美国中部时间2018年11月10日,2018美国心脏协会(AHA)科学年会在美国芝加哥盛大开幕。会议伊始,即公布了新版AHA/ACC胆固醇临床实践指南。旧版指南更新于2013年,距今已有五年时间,在此期间非他汀类药物依折麦布与PCSK9抑制剂相继上市,又有多项重要研究问世,新版指南究竟会作何推荐?

Biophys J:胆固醇水平升高或可影响心脏治疗

2018年8月23日,在线发表于《Biophys J》杂志上的一项研究表明,胆固醇水平升高会影响到钾离子进入心脏的特定离子通道,这可能对未来的心脏治疗产生影响。

胆固醇高能不能吃肉和鸡蛋呢?人们对胆固醇有哪些误解?

胆固醇为什么平白无故地增高呢?原因目前还不十分清楚,可能与胆固醇的吸收增多、合成胆固醇的机能亢进或者与胆固醇的分解代谢减少等有关。

2018年美国降胆固醇治疗新版指南的“四大悬念”

2018年11月10日,2018年AHA/ACC胆固醇临床实践指南即将正式颁布。在血脂管理领域,美国指南一直是全球指南的重要风向标,本次新指南颁布必将引起广泛关注。去年美国颁布新版高血压指南之后,因为高血压诊断标准以及降压目标值的下调,在国内外引起广泛而热烈的讨论,为此有学者推测本次美国新版胆固醇治疗指南也将会有大的变化。目前看来这种可能性并不大,新版降胆固醇指南在原则上应该与上版指南(2013年